Trevi Ptb Ratio vs Ev To Operating Cash Flow Analysis
TRVI Stock | USD 2.88 0.04 1.37% |
Trevi Therapeutics financial indicator trend analysis is much more than just breaking down Trevi Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Trevi Therapeutics is a good investment. Please check the relationship between Trevi Therapeutics Ptb Ratio and its Ev To Operating Cash Flow accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Trevi Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For more detail on how to invest in Trevi Stock please use our How to Invest in Trevi Therapeutics guide.
Ptb Ratio vs Ev To Operating Cash Flow
Ptb Ratio vs Ev To Operating Cash Flow Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Trevi Therapeutics Ptb Ratio account and Ev To Operating Cash Flow. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Trevi Therapeutics' Ptb Ratio and Ev To Operating Cash Flow is 0.88. Overlapping area represents the amount of variation of Ptb Ratio that can explain the historical movement of Ev To Operating Cash Flow in the same time period over historical financial statements of Trevi Therapeutics, assuming nothing else is changed. The correlation between historical values of Trevi Therapeutics' Ptb Ratio and Ev To Operating Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ptb Ratio of Trevi Therapeutics are associated (or correlated) with its Ev To Operating Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ev To Operating Cash Flow has no effect on the direction of Ptb Ratio i.e., Trevi Therapeutics' Ptb Ratio and Ev To Operating Cash Flow go up and down completely randomly.
Correlation Coefficient | 0.88 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Ev To Operating Cash Flow
A valuation metric comparing the company's enterprise value to its operating cash flow, indicating how many dollars of EV are generated for each dollar of operating cash flows.Most indicators from Trevi Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Trevi Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Trevi Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For more detail on how to invest in Trevi Stock please use our How to Invest in Trevi Therapeutics guide.The Trevi Therapeutics' current Tax Provision is estimated to increase to about (66.5 K). The current Selling General Administrative is estimated to decrease to about 7.6 M
Trevi Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Trevi Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Trevi Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 60.0M | 47.1M | 38.5M | 123.0M | 89.4M | 56.3M | |
Other Current Liab | 3.5M | 3.4M | 3.9M | 3.5M | 3.4M | 3.2M | |
Total Current Liabilities | 5.2M | 5.6M | 12.7M | 13.4M | 5.8M | 7.3M | |
Total Stockholder Equity | 54.5M | 27.3M | 17.1M | 107.5M | 82.5M | 41.7M | |
Other Liab | 325K | 460K | 196K | 3K | 2.7K | 2.6K | |
Net Tangible Assets | 54.5M | 27.3M | 17.1M | 107.5M | 123.6M | 129.8M | |
Retained Earnings | (114.2M) | (147.0M) | (180.9M) | (210.1M) | (239.1M) | (227.2M) | |
Accounts Payable | 1.6M | 2.0M | 2.8M | 2.9M | 1.8M | 1.7M | |
Cash | 57.3M | 45.0M | 36.8M | 12.6M | 32.4M | 31.8M | |
Other Assets | 1.6M | 19K | 759.0 | 334K | 205K | 0.0 | |
Cash And Short Term Investments | 57.3M | 45.0M | 36.8M | 12.6M | 83.0M | 87.1M | |
Net Receivables | 184K | 558K | 265K | 241K | 277.2K | 243.5K | |
Common Stock Total Equity | 101K | 18K | 19K | 60K | 69K | 37.0K | |
Inventory | 1.4M | 1.6M | 895K | (241K) | (277.2K) | (263.3K) | |
Other Current Assets | 77K | 108K | 886K | 2.1M | 4.6M | 4.8M | |
Other Stockholder Equity | 168.7M | 174.2M | 198.0M | 317.6M | 321.6M | 179.7M | |
Total Liab | 5.5M | 19.8M | 21.4M | 15.6M | 6.9M | 10.6M | |
Short Long Term Debt | 5.3M | 0.0 | 5.8M | 7M | 6.3M | 4.2M | |
Total Current Assets | 59.6M | 46.3M | 38.0M | 122.6M | 87.5M | 55.5M | |
Accumulated Other Comprehensive Income | (23K) | (46K) | (60.0M) | (122K) | (29K) | (30.5K) | |
Short Term Debt | 99K | 113K | 6.0M | 7.0M | 612K | 581.4K | |
Common Stock | 18K | 19K | 29K | 60K | 68K | 41.7K | |
Property Plant Equipment | 430K | 330K | 184K | 170K | 195.5K | 201.5K | |
Property Plant And Equipment Net | 430K | 330K | 184K | 194K | 1.6M | 1.6M | |
Net Debt | (57.0M) | (30.8M) | (22.2M) | (3.4M) | (31.1M) | (32.6M) | |
Non Current Assets Total | 449K | 862K | 518K | 399K | 1.9M | 1.9M | |
Non Currrent Assets Other | 19K | 532K | 334K | 205K | 297K | 341.9K | |
Common Stock Shares Outstanding | 11.7M | 18.1M | 22.8M | 64.5M | 99.0M | 104.0M | |
Liabilities And Stockholders Equity | 60.0M | 47.1M | 38.5M | 123.0M | 89.4M | 63.0M | |
Non Current Liabilities Total | 257K | 14.3M | 8.7M | 2.2M | 1.0M | 980.4K | |
Net Invested Capital | 54.5M | 41.2M | 31.6M | 116.6M | 82.5M | 41.6M | |
Property Plant And Equipment Gross | 430K | 330K | 366K | 419K | 1.7M | 1.8M | |
Net Working Capital | 54.4M | 40.7M | 25.2M | 109.2M | 81.7M | 53.8M | |
Capital Stock | 18K | 19K | 29K | 60K | 68K | 39.3K |
Currently Active Assets on Macroaxis
When determining whether Trevi Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Trevi Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Trevi Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Trevi Therapeutics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Trevi Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For more detail on how to invest in Trevi Stock please use our How to Invest in Trevi Therapeutics guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trevi Therapeutics. If investors know Trevi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trevi Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.44) | Return On Assets (0.37) | Return On Equity (0.60) |
The market value of Trevi Therapeutics is measured differently than its book value, which is the value of Trevi that is recorded on the company's balance sheet. Investors also form their own opinion of Trevi Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Trevi Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trevi Therapeutics' market value can be influenced by many factors that don't directly affect Trevi Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Trevi Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Trevi Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trevi Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.